{
  "symbol": "HBIO",
  "company_name": "Harvard Bioscience",
  "ir_website": "https://www.harvardbioscience.com/investors",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "News & Events",
          "url": "https://investor.harvardbioscience.com/press-releases",
          "content": "[Skip to content](#lfg-main-content)\n\nOpen Main Menu\n\n[ Home ](https://www.harvardbioscience.com/)\n\nFulltext search\n\nSearch\n\n![Abstract graphic of an eye](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/investor-relations-banner.jpg)\n\nInvestor Relations\n\n# \n\nPress Releases \n\nYear All Years20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999\n\n2024\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience Announces Third Quarter 2024 Financial Results\n\nNovember 7, 2024 \n\nHOLLISTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2024. Jim Green, Chairman and CEO, said, “Our third quarter revenues continued to reflect the effects of the \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-announces-third-quarter-2024-financial)\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET\n\nOctober 29, 2024 \n\nHOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-schedules-third-quarter-2024-earnings)\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024\n\nOctober 3, 2024 \n\nNew products complement an already extensive range of products enabling fundamental advancements in neuroscience research HOLLISTON, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-showcase-innovative-technologies-society)\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting\n\nSeptember 18, 2024 \n\nSolutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development HOLLISTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-showcase-latest-solutions-preclinical-and-0)\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference\n\nSeptember 5, 2024 \n\nHOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Small Cap Virtual Conference on September 18 th , 2024, \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-inc-participate-sidoti-small-cap-virtual)\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience Announces Second Quarter 2024 Financial Results\n\nAugust 8, 2024 \n\nHOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2024. Jim Green, Chairman and CEO, said, “Second quarter revenues reflect a more challenging than expected market \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-announces-second-quarter-2024-financial)\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET\n\nAugust 2, 2024 \n\nHOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to discuss the results at 10:00 a.m. \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-schedules-second-quarter-2024-earnings)\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024\n\nJune 6, 2024 \n\nHOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14 th Annual East Coast IDEAS Conference at the Jay \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-inc-present-and-host-one-one-meetings-14th)\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024\n\nMay 23, 2024 \n\nHOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriott \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-inc-present-jefferies-global-healthcare)\n\nSVG\n\n![Press release](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/svg/article.svg)\n\nPress release\n\nHarvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference\n\nMay 16, 2024 \n\nHOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22 nd , \n\n[Read more](/news-releases/news-release-details/harvard-bioscience-inc-participate-benchmark-healthcare-house)\n\nDisplaying 1 - 10 of 17 \n\n[ Printed Materials ](/printed-materials \"Printed Materials\")\n\n[ Email Alerts ](/email-alerts \"Email Alerts\")\n\n[ RSS  ](/rss-news-feeds \"RSS \")\n\n[ Print ]( \"Print\")\n\n[ Share ]( \"Share\")\n\n  * [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestor.harvardbioscience.com%2Fpress-releases \"Facebook\")\n  * [Twitter](https://twitter.com/intent/tweet?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fpress-releases \"Twitter\")\n  * [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fpress-releases \"LinkedIn\")\n\n\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking \"Accept,\" you consent to our use of cookies. [Our Cookie Policy](https://www.harvardbioscience.com/cookie-policy)\n\nreject accept\n"
        },
        {
          "title": "Corporate Governance",
          "url": "https://investor.harvardbioscience.com/corporate-governance",
          "content": "[Skip to content](#lfg-main-content)\n\nOpen Main Menu\n\n[ Home ](https://www.harvardbioscience.com/)\n\nFulltext search\n\nSearch\n\n![Abstract graphic of an eye](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/investor-relations-banner.jpg)\n\nInvestor Relations\n\n# \n\nCorporate Governance \n\nThe Board of Directors of Harvard Bioscience, Inc. (the \"Company\") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.\n\n##  Our Code of Business Conduct and Ethics \n\n[Code of Business Conduct and Ethics](/static-files/5c9c2924-46a3-4335-9e59-7e146343626a)\n\n##  Committee Charters \n\n[Audit Committee Charter](/static-files/aad8cc27-ee16-4de0-9ddf-3c1166eb9829)\n\n[Duties and Responsibilities of the Lead Independent Director](/static-files/86238b87-5b21-4d6c-8635-d76b627df52e)\n\n[Compensation Committee Charter](/static-files/cbd25bd0-4438-4999-9367-03e916887370)\n\n[Nominating and Governance Committee Charter](/static-files/8e4b1613-6bdb-4d00-ab3d-36ce4080684a)\n\n##  Conflict Minerals \n\n[Conflict Minerals Policy ](/static-files/04a54b37-691f-496e-8581-140c038382d9)\n\n[2023 Conflict Minerals Report Template (CMRT)](/static-files/dd4a4839-3b87-42d0-b356-17717c2a6b83)\n\n[2023 Form SD](/static-files/0db8b998-5a6f-4b09-baf8-4e86047a513e)\n\n[ Printed Materials ](/printed-materials \"Printed Materials\")\n\n[ Email Alerts ](/email-alerts \"Email Alerts\")\n\n[ RSS  ](/rss-news-feeds \"RSS \")\n\n[ Print ]( \"Print\")\n\n[ Share ]( \"Share\")\n\n  * [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestor.harvardbioscience.com%2Fcorporate-governance \"Facebook\")\n  * [Twitter](https://twitter.com/intent/tweet?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fcorporate-governance \"Twitter\")\n  * [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fcorporate-governance \"LinkedIn\")\n\n\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking \"Accept,\" you consent to our use of cookies. [Our Cookie Policy](https://www.harvardbioscience.com/cookie-policy)\n\nreject accept\n"
        },
        {
          "title": "Financials",
          "url": "https://investor.harvardbioscience.com/financial-information",
          "content": "[Skip to content](#lfg-main-content)\n\nOpen Main Menu\n\n[ Home ](https://www.harvardbioscience.com/)\n\nFulltext search\n\nSearch\n\n![Abstract graphic of an eye](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/investor-relations-banner.jpg)\n\nInvestor Relations\n\n# \n\nFinancials & Filings \n\n[Show all](#)\n\n## Q3 2024\n\n  * [Harvard Bioscience Announces Third Quarter 2024 Financial Results](/news-releases/news-release-details/harvard-bioscience-announces-third-quarter-2024-financial)\n\n  * [Q3 2024 Harvard Bioscience, Inc. Earnings Conference Call](/events/event-details/q3-2024-harvard-bioscience-inc-earnings-conference-call)\n\n  * [Q3 - 2024 HBIO Quarterly Earnings Presentation](/static-files/134a1bfb-967d-4472-98f7-54caaa35d607 \"Q3 2024 - HBIO Earnings Presentation \\(Updated November 21 2024\\).pdf\") 663 KB\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001171843-24-006181)\n\n\n\n\n## Proxy Statements\n\n[Filing date ](?field_nir_sec_form_group_target_id%5B491%5D=491&field_nir_sec_form_group_target_id_1%5B1946%5D=1946&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | View  \n---|---  \nApr 03, 2024 |  [0001171843-24-001813.pdf](/static-files/939a613f-feeb-41e9-9121-17a540b23758) [0001171843-24-001813.rtf](/static-files/5cfb633e-c8d0-4d6e-87e5-2c656ab9cbec) [0001171843-24-001813.xls](/static-files/c3daeee9-a0f3-4409-80d2-77c974ecb674) [View HTML](/node/17361/html)  \nApr 05, 2023 |  [0001171843-23-002149.pdf](/static-files/69532dde-abeb-4fb8-b120-36db6c8d408e) [0001171843-23-002149.rtf](/static-files/771aba01-058c-4a9c-b02c-136ba561a93d) [0001171843-23-002149.xls](/static-files/54706d64-7e9d-402e-ba4f-186504bdf06e) [View HTML](/node/16846/html)  \n  \n##  Form 10-K\n\n[Filing date ](?field_nir_sec_form_group_target_id_1%5B611%5D=611&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | View  \n---|---  \nMar 07, 2024 | [View HTML](/node/17306/html) [0001171843-24-001239.pdf](/static-files/4a8ca2da-bae4-4b70-872b-e2bcef3b5d4d) [0001171843-24-001239.rtf](/static-files/5e6b38a2-b5b4-4571-8e2f-a3ae4e77b229) [0001171843-24-001239.xls](/static-files/e30a3137-1900-4370-9c86-82b3902a2bec) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001171843-24-001239)  \nMar 09, 2023 | [View HTML](/node/16776/html) [0001171843-23-001566.pdf](/static-files/0ff9c28e-6b1b-42d3-9fe1-d595743c4aa2) [0001171843-23-001566.rtf](/static-files/4f091c28-580c-4a0b-8f22-4ec021e24956) [0001171843-23-001566.xls](/static-files/ed63e263-cf45-4498-99be-1329ce8b969d) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001171843-23-001566)  \n  \n## Form 10-Q\n\n[Filing date ](?field_nir_sec_form_group_target_id%5B496%5D=496&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | View  \n---|---  \nNov 08, 2024 |  [0001171843-24-006181.pdf](/static-files/b33931ef-5d6d-4ecf-8401-633e8d0eb308) [0001171843-24-006181.rtf](/static-files/0292dd22-bf84-4504-8715-a595fa867320) [0001171843-24-006181.xls](/static-files/396cc13b-23c7-4b55-9604-2a6660a279a0) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001171843-24-006181) [View HTML](/node/17656/html)  \nAug 08, 2024 |  [0001171843-24-004564.pdf](/static-files/5ada0f54-a435-4080-b10c-c5720b013642) [0001171843-24-004564.rtf](/static-files/9e7a07cb-2df2-4a3b-bfd6-a7ffc94226be) [0001171843-24-004564.xls](/static-files/d94b6b5f-60e7-4a14-91ed-06239ecea100) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001171843-24-004564) [View HTML](/node/17571/html)  \n  \n[ Printed Materials ](/printed-materials \"Printed Materials\")\n\n[ Email Alerts ](/email-alerts \"Email Alerts\")\n\n[ RSS  ](/rss-news-feeds \"RSS \")\n\n[ Print ]( \"Print\")\n\n[ Share ]( \"Share\")\n\n  * [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestor.harvardbioscience.com%2Ffinancial-information \"Facebook\")\n  * [Twitter](https://twitter.com/intent/tweet?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Ffinancial-information \"Twitter\")\n  * [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Ffinancial-information \"LinkedIn\")\n\n\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking \"Accept,\" you consent to our use of cookies. [Our Cookie Policy](https://www.harvardbioscience.com/cookie-policy)\n\nreject accept\n"
        },
        {
          "title": "Stock",
          "url": "https://investor.harvardbioscience.com/stock-information",
          "content": "[Skip to content](#lfg-main-content)\n\nOpen Main Menu\n\n[ Home ](https://www.harvardbioscience.com/)\n\nFulltext search\n\nSearch\n\n![Abstract graphic of an eye](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/investor-relations-banner.jpg)\n\nInvestor Relations\n\n# \n\nStock Information \n\n## Stock Quote\n\nChange\n\nVolume\n\nToday's Open\n\nPrevious Close\n\nToday's High\n\nToday's Low\n\n52 Week High\n\n52 Week Low\n\n## Stock Chart\n\nMinimum 15 minutes delayed. Source: LSEG\n\n[ Printed Materials ](/printed-materials \"Printed Materials\")\n\n[ Email Alerts ](/email-alerts \"Email Alerts\")\n\n[ RSS  ](/rss-news-feeds \"RSS \")\n\n[ Print ]( \"Print\")\n\n[ Share ]( \"Share\")\n\n  * [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestor.harvardbioscience.com%2Fstock-information \"Facebook\")\n  * [Twitter](https://twitter.com/intent/tweet?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fstock-information \"Twitter\")\n  * [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fstock-information \"LinkedIn\")\n\n\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking \"Accept,\" you consent to our use of cookies. [Our Cookie Policy](https://www.harvardbioscience.com/cookie-policy)\n\nreject accept\n"
        },
        {
          "title": "Analyst Coverage",
          "url": "https://investor.harvardbioscience.com/stock-information/analyst-coverage",
          "content": "[Skip to content](#lfg-main-content)\n\nOpen Main Menu\n\n[ Home ](https://www.harvardbioscience.com/)\n\nFulltext search\n\nSearch\n\n![Abstract graphic of an eye](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/investor-relations-banner.jpg)\n\nInvestor Relations\n\n# \n\nAnalyst Coverage \n\nHarvard Bioscience, Inc. is covered by the following analysts.\n\nFirm | Analyst  \n---|---  \nKeyBanc Capital Market |  Paul Knight   \nSingular Research |  Staff   \nThe Benchmark Company  |  Bruce Jackson   \n  \nHarvard Bioscience, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Harvard Bioscience, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Harvard Bioscience, Inc. or its management. Harvard Bioscience, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n\n[ Printed Materials ](/printed-materials \"Printed Materials\")\n\n[ Email Alerts ](/email-alerts \"Email Alerts\")\n\n[ RSS  ](/rss-news-feeds \"RSS \")\n\n[ Print ]( \"Print\")\n\n[ Share ]( \"Share\")\n\n  * [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestor.harvardbioscience.com%2Fstock-information%2Fanalyst-coverage \"Facebook\")\n  * [Twitter](https://twitter.com/intent/tweet?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fstock-information%2Fanalyst-coverage \"Twitter\")\n  * [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fstock-information%2Fanalyst-coverage \"LinkedIn\")\n\n\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking \"Accept,\" you consent to our use of cookies. [Our Cookie Policy](https://www.harvardbioscience.com/cookie-policy)\n\nreject accept\n"
        },
        {
          "title": "Investor FAQs",
          "url": "https://investor.harvardbioscience.com/investor-faqs",
          "content": "[Skip to content](#lfg-main-content)\n\nOpen Main Menu\n\n[ Home ](https://www.harvardbioscience.com/)\n\nFulltext search\n\nSearch\n\n![Abstract graphic of an eye](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/investor-relations-banner.jpg)\n\nInvestor Relations\n\n# \n\nInvestor FAQs \n\n[Show All](#)\n\nWhere is Harvard Bioscience, Inc.'s stock traded?\n\nHarvard Bioscience, Inc. common stock is traded on the NASDAQ National Market under the ticker symbol \"HBIO.\"\n\nWhere are Harvard Bioscience, Inc.'s headquarters located? \n\n84 October Hill Road, Suite 10 Holliston, MA 01746-1371\n\nCan I buy Harvard Bioscience, Inc.'s stock directly from the Company? \n\nHarvard Bioscience, Inc. does not offer a direct stock purchase plan. Shares of the Company should be purchased through a broker.\n\nDoes Harvard Bioscience, Inc. pay a dividend? \n\nHarvard Bioscience, Inc. does not pay a dividend at this time.\n\nWho is Harvard Bioscience, Inc. 's transfer agent? \n\nComputershare, Inc. 150 Royall Street Suite 101 Canton, Massachusetts 02021 800-942-5909 or 312-360-5195 Monday – Friday 8 AM – 5 PM ET\n\nWho do I contact about replacement of stock certificates?\n\nTo replace lost certificates, contact the transfer agent, Computershare, Inc. at 800-942-5909 or 312-360-5195 Monday – Friday 8 AM – 5 PM ET\n\nWhat is Harvard Bioscience, Inc.'s fiscal year? \n\nHarvard Bioscience, Inc.'s fiscal year ends December 31st. Fiscal First Quarter ends 3/31, Fiscal Second Quarter ends 6/30, Fiscal Third Quarter ends 9/30 and Fiscal Fourth Quarter ends 12/31.\n\n[ Printed Materials ](/printed-materials \"Printed Materials\")\n\n[ Email Alerts ](/email-alerts \"Email Alerts\")\n\n[ RSS  ](/rss-news-feeds \"RSS \")\n\n[ Print ]( \"Print\")\n\n[ Share ]( \"Share\")\n\n  * [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestor.harvardbioscience.com%2Finvestor-faqs \"Facebook\")\n  * [Twitter](https://twitter.com/intent/tweet?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Finvestor-faqs \"Twitter\")\n  * [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Finvestor-faqs \"LinkedIn\")\n\n\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking \"Accept,\" you consent to our use of cookies. [Our Cookie Policy](https://www.harvardbioscience.com/cookie-policy)\n\nreject accept\n"
        },
        {
          "title": "CONTACT US",
          "url": "https://investor.harvardbioscience.com/contact-us",
          "content": "[Skip to content](#lfg-main-content)\n\nOpen Main Menu\n\n[ Home ](https://www.harvardbioscience.com/)\n\nFulltext search\n\nSearch\n\n![Abstract graphic of an eye](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/investor-relations-banner.jpg)\n\nInvestor Relations\n\n# \n\nContact Us \n\n### Investor Relations\n\n**Three Part Advisors** Sandy Martin/Erol Girgin/William Shelmire E-mail: HBIO@threepa.com 214-616-2207\n\n### Transfer Agent\n\nComputershare, Inc. 150 Royall Street Suite 101 Canton, Massachusetts 02021 800-942-5909 or 312-360-5195 Monday – Friday 8 AM – 5 PM ET\n\nPlease submit questions for investor relations using the form below.\n\n* Indicates required field\n\nName\n\nEmail\n\nSubject\n\nComments\n\nData Processing Notice & Consent\n\nI consent to Harvard Bioscience processing my personal data for the specific purposes set out in our [Privacy Policy](http://www.harvardbioscience.com/about-us/privacy-policy/) and agree to the Harvard Bioscience [Terms and Conditions](http://www.harvardbioscience.com/about-us/terms-conditions/) of use.*\n\nLeave this field blank\n\n[ Printed Materials ](/printed-materials \"Printed Materials\")\n\n[ Email Alerts ](/email-alerts \"Email Alerts\")\n\n[ RSS  ](/rss-news-feeds \"RSS \")\n\n[ Print ]( \"Print\")\n\n[ Share ]( \"Share\")\n\n  * [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestor.harvardbioscience.com%2Fcontact-us \"Facebook\")\n  * [Twitter](https://twitter.com/intent/tweet?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fcontact-us \"Twitter\")\n  * [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Fcontact-us \"LinkedIn\")\n\n\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking \"Accept,\" you consent to our use of cookies. [Our Cookie Policy](https://www.harvardbioscience.com/cookie-policy)\n\nreject accept\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://investor.harvardbioscience.com/email-alerts",
          "content": "[Skip to content](#lfg-main-content)\n\nOpen Main Menu\n\n[ Home ](https://www.harvardbioscience.com/)\n\nFulltext search\n\nSearch\n\n![Abstract graphic of an eye](/sites/g/files/knoqqb78791/themes/site/nir_pid2180/dist/images/investor-relations-banner.jpg)\n\nInvestor Relations\n\n# \n\nEmail Alerts \n\nYou may automatically receive Harvard Bioscience, Inc. financial information by email. Please enter your preferences for email notifications below and click submit.\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote By Email  \nAll SEC Filings  \nInsider Transactions  \nPress Releases  \nWeekly Summary  \n  \nEmail\n\nLeave this field blank\n\n[Unsubscribe from Investor Relations email alerts](/unsubscribe)\n\nOur email alerts provide automated opt-out methods as well as complete contact information.\n\n[ Printed Materials ](/printed-materials \"Printed Materials\")\n\n[ Email Alerts ](/email-alerts \"Email Alerts\")\n\n[ RSS  ](/rss-news-feeds \"RSS \")\n\n[ Print ]( \"Print\")\n\n[ Share ]( \"Share\")\n\n  * [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestor.harvardbioscience.com%2Femail-alerts \"Facebook\")\n  * [Twitter](https://twitter.com/intent/tweet?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Femail-alerts \"Twitter\")\n  * [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Finvestor.harvardbioscience.com%2Femail-alerts \"LinkedIn\")\n\n\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking \"Accept,\" you consent to our use of cookies. [Our Cookie Policy](https://www.harvardbioscience.com/cookie-policy)\n\nreject accept\n"
        }
      ]
    }
  ]
}